Concorde Asset Management’s Health Catalyst HCAT Stock Holding History

Concorde Asset Management’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,080	Closed	-$238K	–	209
2021 Q1	$238K	Sell	5,080 -21,793	-81%	-$1.06M	0.14%	181
2020 Q4	$1.17M	Sell	26,873 -1,097	-4%	-$40.5K	0.65%	40
2020 Q3	$1.02M	Buy	+27,970	New	+$950K	0.58%	46

Other funds holding HCAT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Concorde Asset Management's HCAT Position: Q2 2021 in Review

Concorde Asset Management sold out of Health Catalyst (HCAT) in Q2 2021, closing a stake of 5,080 shares — an estimated $238K sold.

Concorde Asset Management first reported a position in HCAT in Q3 2020 and held it in 3 quarters. The position peaked at $1.17M in Q4 2020. 198 funds tracked by Wall St. Rank hold HCAT as of Q2 2021.

Concorde Asset Management reported no remaining Health Catalyst position as of Q2 2021 after selling out during the quarter.
Concorde Asset Management sold 5,080 Health Catalyst shares in Q2 2021, an estimated $238K.
Concorde Asset Management first reported a position in Health Catalyst in Q3 2020 and held it in 3 quarters.
Concorde Asset Management's Health Catalyst position peaked at $1.17M in Q4 2020.
198 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2021.

Based on Concorde Asset Management's 13F filing for Q2 2021, filed 20 Jul 2021.